<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="uslm.css">
        <link rel="stylesheet" href="style.css">
        <script lang="text/javascript" src="omni.js" defer></script>
        <title> Omnibuster Section </title>
    </head>

    <body>
        <div class="section">
            <h1> Section s3856 </h1>
            <div class="buttons">
                <div>
                    <button onclick="highlightSelection();">Highlight Text</button>
                </div>
                <div>
                    <button onclick="annotateSelection();">[Not working] Annotate Text</button>
                </div>
            </div>
            <p> <section id="d3355e28457" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3856" style="-uslm-lc:I650144"><num value="3856">SEC. 3856. </num><heading>TECHNICAL CORRECTIONS.</heading><subsection class="indent0 fontsize10" id="d3355e28462" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3856/a" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">(a) </num><heading><inline class="small-caps">Imports and Exports</inline>.—</heading><content>Section 801(e)(4)(E)(iii) of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section381&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s381/e/4/E/iii">21 U.S.C. 381(e)(4)(E)(iii)</ref></a>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="delete">striking</amendingAction> “<quotedText>subparagraph</quotedText>” each place such term appears and <amendingAction type="insert">inserting</amendingAction> “<quotedText>paragraph</quotedText>”.</content>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e28485" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3856/b" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">(b) </num><heading><inline class="small-caps">FDA Reauthorization Act of 2017</inline>.—</heading><paragraph class="indent1 fontsize10" id="d3355e28492" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3856/b/1" role="instruction" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Section 905(b)(4) of the FDA Reauthorization Act of 2017 (<ref href="/us/pl/115/52">Public Law 115–52</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="delete">striking</amendingAction> “<quotedText>Section 744H(e)(2)(B)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>Section 744H(f)(2)(B)</quotedText>”.</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e28515" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3856/b/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><heading><inline class="small-caps">Effective date</inline>.—</heading><content>The amendment made by paragraph (1) shall take effect as of the enactment of the FDA Reauthorization Act of 2017 (<ref href="/us/pl/115/52">Public Law 115–52</ref>).</content>
</paragraph>
</subsection>
</section>
            </p>
        </div>  
    </body>